Does losing weight on a GLP-1 mean losing muscle in perimenopause?

Dr. Linda's take

If you are in perimenopause and thinking about starting one of these medications, there is a specific worry I hear often, and it is a sharp one: "My body is already losing muscle. Is this medication going to take more of it?"

That question deserves a real answer rather than reassurance. It is also a question most weight-loss content skips entirely, because most of it is still written as though the only number that matters is the one on the scale. In perimenopause, the scale is close to the least interesting measurement in the room. What is changing underneath it matters far more.

So let us look at what perimenopause actually does to muscle, what the trial data show about where that lost weight comes from, and where the evidence genuinely runs out. This is general education, not a recommendation about what you personally should do.

What is already happening to your muscle in perimenopause?

Here is the part that reframes the whole question. In the Study of Women's Health Across the Nation, a long-running study that tracked women with DXA body scans through the menopause transition, lean mass declined during the transition while the rate of fat gain roughly doubled. Fat mass rose about 1.0% per year before the transition and accelerated to about 1.7% per year during it.

But the same research found something people rarely hear: the rate of total weight gain did not change at the start of the menopause transition. In other words, the scale is largely tracking your age, while your body composition is tracking menopause. That is why so many women say the number barely moved but nothing fits the same way.

Muscle loss with age is not unique to menopause either. After about age 30, muscle mass declines at a rate of roughly 3% to 8% per decade.

If you want the fuller picture of why perimenopausal weight changes happen at all, we cover that separately in why perimenopause weight gain happens even when you haven't changed your diet. This article stays on the muscle question.

The upshot: you are not starting from a neutral baseline. Lean mass is already drifting down. That is exactly why the muscle question is worth asking before starting any weight-loss medication, not after.

Do these medications even work during perimenopause?

Reasonable question, given that women in the menopause transition are rarely studied as their own group.

A post hoc analysis of the SURMOUNT trial program sorted women by reproductive stage and looked at how much weight they lost on tirzepatide. In SURMOUNT-1, weight reduction was significantly greater with tirzepatide than placebo for women in premenopause (26% vs 2%), perimenopause (23% vs 3%), and postmenopause (23% vs 3%). The authors concluded that the medication was associated with significant reductions in body weight and waist circumference regardless of reproductive stage.

Two honest caveats belong right next to that result. This was a post hoc analysis, meaning the reproductive-stage groups were sorted out after the trial rather than being what the trial was built to test, and the authors themselves note that some women in the perimenopause subgroup may have been miscategorized. The second caveat is about which medicine was studied. Tirzepatide is a GIP receptor and GLP-1 receptor agonist, so it is not the same molecule as semaglutide. We found no equivalent published reproductive-stage analysis for semaglutide.

Does the weight you lose come out of muscle?

This is the heart of it, and the data are more reassuring than the internet suggests, though not perfectly clean.

In a DXA body-composition substudy of SURMOUNT-1, 74% of the weight lost on tirzepatide was fat mass and 26% was lean mass. In the placebo group, the split was 75% fat and 25% lean.

Read that comparison twice, because it is the whole answer. Lean mass does fall in absolute terms, and it falls more on the medication than on placebo, with mean lean mass changing about -10.9% on tirzepatide versus about -2.6% on placebo. But the proportion of the lost weight that came from lean tissue was essentially the same as placebo. Losing some lean mass is what meaningful weight loss does, in nearly the same ratio, whether a medication drives it or not. It is not a special penalty the drug imposes.

There is also direct evidence on semaglutide and muscle function. In the SEMALEAN study, which followed people on semaglutide for a year, lean mass fell by about 3.0 kg over the first seven months and then stabilized through month twelve. Meanwhile lean mass as a proportion of total body mass increased, and handgrip strength, a standard measure of real-world muscle function, increased at both seven and twelve months.

That last detail matters. Participants ended up with proportionally more lean tissue and a stronger grip, even though absolute lean mass had gone down. Strength did not follow the scale down. SEMALEAN was an observational cohort rather than a randomized trial, so it carries less weight than SURMOUNT-1, and it is worth reading with that limitation in mind.

What does the evidence still not tell us?

Here is the honest boundary of what is known. The reproductive-stage analysis above measured body weight and waist circumference, not lean mass. The body-composition substudies measured lean mass, but did not break their results out by menopausal stage. We could not find a study that puts those two questions together, so the specific question of muscle preservation in perimenopausal women on these medications has not been directly answered.

So the sensible reasoning, which I want to label clearly as reasoning rather than as a cited finding, goes like this: perimenopause is already a period of lean-mass loss, and weight loss of any kind takes some lean mass with it. That makes muscle-supporting habits, particularly resistance training and adequate protein, a reasonable thing to raise with a clinician alongside any weight-loss medication. We go deeper on that in our guide to protecting muscle during weight loss. What I cannot tell you is that a study has proven that combination works specifically in perimenopausal women, because we could not find one.

What should you ask your clinician?

If you want a structured way into that conversation, Body Good Studio's quiz maps your symptoms to a starting point before you speak with a clinician.

Frequently asked questions

Does perimenopause itself cause muscle loss?

Lean mass declines during the menopause transition, and fat gain accelerates over the same window. Separately, muscle mass declines with age at roughly 3% to 8% per decade after about age 30. Both processes are underway at once in midlife.

Do GLP-1 medications work in perimenopausal women?

In a post hoc analysis of SURMOUNT-1, women in perimenopause lost significantly more weight on tirzepatide than on placebo (23% vs 3%). That analysis was not what the trial was designed to test, and no equivalent published analysis exists for semaglutide.

What share of GLP-1 weight loss is muscle?

In the SURMOUNT-1 body-composition substudy, 74% of the weight lost on tirzepatide was fat and 26% was lean mass, compared with 75% fat and 25% lean on placebo. The ratio was close to what happened without the medication.

Does losing lean mass mean losing strength?

Not necessarily. In the SEMALEAN study of semaglutide, absolute lean mass fell over the first seven months and then stabilized, while lean mass as a proportion of body mass increased and handgrip strength rose at both seven and twelve months. That was an observational cohort, not a randomized trial.

Has anyone studied muscle preservation specifically in perimenopausal women on these medications?

We could not find one. The available evidence covers reproductive stage and body composition separately: one analysis looked at weight loss by reproductive stage, and others looked at lean mass without sorting by menopausal stage. That is a real gap worth naming rather than glossing over.

References

1. Greendale GA, Sternfeld B, Huang M, et al. (2019). Changes in body composition and weight during the menopause transition. JCI Insight, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC6483504/ (Accessed 2026-07-14).
2. Hurtado MD, Saadedine M, Kapoor E, Shufelt CL, Faubion SS (2024). Weight Gain in Midlife Women. Current Obesity Reports, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11150086/ (Accessed 2026-07-14).
3. Tchang BG, Mihai AC, Stefanski A, et al. (2025). Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring), via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC12015656/ (Accessed 2026-07-14).
4. Look M, Dunn JP, Kushner RF, et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11965027/ (Accessed 2026-07-14).
5. Alissou M, Demangeat T, Folope V, et al. (2026). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes, Obesity and Metabolism, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC12673431/ (Accessed 2026-07-14).
6. Eli Lilly and Company / U.S. Food and Drug Administration (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-14).